Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 5/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 5/20 | 0.42 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663151 | 0.90 | CTSL (0.44) | AVPR1ANAALAD2NMUR2NMUR1TACR3 | |
| SCHEMBL1662080 | 0.90 | BACE1 (0.49) | AVPR1ANAALAD2NMUR2NMUR1TACR3 | |
| SCHEMBL1661229 | 0.89 | ACE (0.51) | AVPR1AACENAALAD2 | |
| SCHEMBL12793435 | 0.86 | NPY4R (0.49) | TACR3 | |
| SCHEMBL1662059 | 0.84 | CTSL (0.54) | — | |
| SCHEMBL19252727 | 0.83 | FOLH1 (0.47) | NAALAD2 | |
| SCHEMBL1661011 | 0.83 | ACE (0.48) | AVPR1AACENMUR2NMUR1TACR3 | |
| SCHEMBL1663148 | 0.79 | APC (0.51) | AVPR1AACENAALAD2 | |
| SCHEMBL13731613 | 0.79 | NAALAD2 (0.40) | AVPR1AACENAALAD2NMUR2NMUR1 | |
| SCHEMBL1660926 | 0.78 | CTSL (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | AVPR1A 4789/4885ACE 2709/4885NAALAD2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.